Venture capital firms launch clinical trial tech company with $203M in funding

Paradigm, a clinical trial technology company, has launched out of stealth with $203 million in Series A funding.

Paradigm will use the money to build a clinical research platform for provider and biopharmaceutical customers. The company has also acquired Deep Lens, a clinical trial patient recruitment company focused on oncology, for an undisclosed price.

Paradigm was conceived by venture capital firm ARCH Venture Partners and co-created by…